

Title: Epidemiology, clinical presentation and management of COVID-19 associated Mucormycosis: A single center experience from Pune, Western India.

Authors: Ameet Dravid MD ¹, Reema Kashiva MD ², Zafer Khan MD ³, Balasaheb Bande ³, Danish Memon MD ², Aparna Kodre MD ², Prashant Potdar MD ², Milind Mane MD ³, Asir Tamboli MD ³, Vishal Pawar MD ³, Dattatraya Patil MD ³, Debashis Banerjee MD ³, Kailas Bhoite ³, Akshay Shinde MD ³, Reshma Pharande MBBS ³, Suraj Kalyani MBBS ³, Prathamesh Raut MBBS ³, Madhura Bapte MD ³, Charlotte Saldanha MD ³, Dinesh Chandak MD ³, Fouzia Ajani MD ³, Anshul Mehta MBBS ², M Sateesh Reddy MBBS ², Krushnadas Bhayani MBBS ², S S Laxmi MBBS ², P D Vishnu MBBS ², Shipra Srivastava MBBS ², Shubham Khandelwal MBBS ², Sailee More MBBS ², Atif Shakeel MBBS ², Mohit Pawar MBBS ², Pranava Nande MBBS ², Amol Harshe MD ⁴, Sagar Kadam MD ⁵, Sudhir Hallikar MD ⁶, Nudrat Kamal MD ⁶, Danish Andrabi MD ⁶, Sachin Bodhale MD ⁷, Akshay Raut BDS ⁸, Pushkar Gawande BDS ⁸, Ankush Bhandari BDS ⁸, Nilesh Wasmatkar MD ⁹, Adnanali Sarkar MD ⁹, Sangeeta Chandrashekhar MD ⁹, Pallavi Butiyani MD ⁹, Geetanjali Akhade MD ⁹, Aditi Abnave MD ⁹, Chandrashekhar Raman MD ¹⁰, Siraj Basade MD ¹⁰, Uma Mahajan M.Sc ¹¹, Gaurav Joshi MBA ¹², Dilip Mane MD ²

Author Affiliations:

1 – Department of Infectious diseases and HIV/AIDS, Noble hospitals and Research Centre, Pune, Maharashtra, India

2 – Department of Medicine, Noble hospital and Research Centre, Pune, Maharashtra, India

3 - Department of Critical Care Medicine, Noble hospital and Research Centre, Pune, Maharashtra, India

4 – Department of Pathology, Noble hospital and Research Centre, Pune, Maharashtra, India

5 - Department of Radiology, Noble hospital and Research Centre, Pune, Maharashtra, India

6 – Department of Otorhinolaryngology, Noble hospital and Research Centre, Pune, Maharashtra, India

29 7 – Department of Ophthalmology, Noble hospital and Research Centre, Pune, Maharashtra,
30 India

31 8 - Department of Maxillo-facial surgery, Noble hospital and Research Centre, Pune,
32 Maharashtra, India

33 9 - Department of Anesthesia, Noble hospital and Research Centre, Pune, Maharashtra, India

34 10- Department of Neurosurgery, Noble hospital and Research Centre, Pune, Maharashtra, India

35 11 – Statistician, VMK Diagnostics private limited, Pune, Maharashtra, India.

36 12 – Independent statistical consultant, Chicago, USA.

37

38 **Email addresses of authors:**

39 Ameet Dravid – ameet.dravid@gmail.com, Reema Kashiva – reemakashiva@gmail.com, Zafer
40 Khan – zafer_a_khan@yahoo.co.in, Balasaheb Bande – drbandebd@hotmail.com, Danish
41 Memon – danish1331@yahoo.co.in, Aparna Kodre – draparnankodre@gmail.com, Prashant
42 Potdar – pashya2511@gmail.com, Milind Mane – drmilind.mane@gmail.com, Asir Tamboli –
43 drasirtamboli@gmail.com, Vishal Pawar – dr.vishal.d.pawar@gmail.com, Dattatraya Patil –
44 drdattapatil05@gmail.com, Debashis Banerjee – debaz2009@gmail.com , Kailas Bhoite –
45 kailasbhoite1978@gmail.com, Akshay Shinde – dr.akshay7@gmail.com, Reshma Pharande –
46 reshma.pharande97@gmail.com, Suraj Kalyani – surajkalyani@gmail.com , Prathamesh Raut –
47 rautlesh@gmail.com , Madhura Bapte – madhuraparth@gmail.com, Charlotte Saldanha –
48 charlotte2491@gmail.com, Dinesh Chandak – dineshchandak444@gmail.com, Fouzia Ajani –
49 drfouziahirani@gmail.com, Anshul Mehta – anshroks.25@gmail.com , M Sateesh Reddy –
50 satishat321@gmail.com , Krushnadas Bhayani – kbhayani321@gmail.com, S S Laxmi –
51 drsslakshmiatl@gmail.com , P D Vishnu – p.d_vishnu@yahoo.co.in, Shipra Srivastava –
52 srivastavashipra51@gmail.com, Shubham Khandelwal – shubh.joyrider@gmail.com, Sailee
53 More – drsaileemore@gmail.com, Atif Shakeel – khanaatif009@gmail.com , Mohit Pawar –
54 mohitpawar2915@gmail.com, Pranava Nande – pranavanande4@gmail.com, Amol Harshe –
55 dramolh@yahoo.co.in , Sagar Kadam – drsagarkadam@gmail.com , Sudhir Halikar –
56 halikarsudhir@gmail.com, Nudrat Kamal- nudratkamal86@gmail.com , Danish Andrabi –
57 danish_andrabi@yahoo.co.in, Sachin Bodhale – drsrbl@gmail.com, Akshay Raut –
58 akshayraut8@gmail.com, Pushkar Gawande – gawandepushkar@gmail.com, Ankush Bhandari –

59 dr.ankushbhandari@yahoo.com, Nilesh Wasmatkar – drnileshkw@gmail.com, Adnanali Sarkar
60 – adnansarkar2@gmail.com, Sangeeta Chandrashekhar – drsangeet15@rediffmail.com, Pallavi
61 Butiyani – pallavibutiyani@gmail.com, Geetanjali Akhade – dangat.geeta@gmail.com, Aditi
62 Abnave – abnaveaditi@gmail.com, Chandrashekhar Raman – drshekhar71@hotmail.com, Siraj
63 Basade - siraj582@yahoo.com, Uma Mahajan – umasmahajan@gmail.com , Gaurav Joshi –
64 gaurav.arun.joshi@gmail.com, Dilip Mane – dileep.mane@yahoo.co.in.

65

66 **Corresponding Author** – Ameet Dravid, Email – ameet.dravid@gmail.com

67

68 **Abbreviations:**

69 Severe acute respiratory syndrome coronavirus 2 - SARS-CoV-2; coronavirus disease 2019-
70 COVID-19; World health organization – WHO; COVID-19 associated Mucormycosis – CAM;
71 C-reactive protein – CRP; lactate dehydrogenase – LDH; Interleukin – 6 - IL-6; Interferon
72 Gamma - IFN- γ ; diabetes mellitus - DM; Tocilizumab - TCZ; cytokine release syndrome - CRS;
73 diabetic ketoacidosis - DKA; Rhino-orbito-cerebral mucormycosis - ROCM; Noble hospital and
74 Research Centre - NHRC; High resolution computerized tomography scan - HRCT ; oxygen
75 saturation - SpO₂ ; ratio of arterial partial pressure of oxygen to fraction of inspired oxygen-
76 PaO₂/FiO₂; Functional endoscopic paranasal sinus surgery - FESS; Liposomal Amphotericin B -
77 LAmB; reverse transcription PCR- RT-PCR; Intensive care unit - ICU; Central nervous system -
78 CNS; institutional review board - IRB; interquartile range - IQR; absolute neutrophil count -
79 ANC ; absolute lymphocyte count - ALC; Intravenous - IV; acute respiratory distress syndrome
80 – ARDS.

81

82

83

84

85

86

87

88

89 **Abstract:**

90 **Background:** The second COVID-19 wave in India, triggered by the Delta variant, has been
91 associated with an unprecedented increase in cases of COVID-19 associated
92 Mucormycosis(CAM), mainly Rhino-orbito-cerebral mucormycosis(ROCM).The primary reason
93 appears to be an unusual alignment of multiple risk factors in patients like prevalence of hypoxia,
94 uncontrolled diabetes mellitus, indiscriminate use of steroids, high iron levels and immune
95 dysfunction.

96 **Methods:** This retrospective cohort study was conducted at Noble hospital and Research Centre
97 (NHRC), Pune, Western India between 1st April 2020 and 1st August 2021 to identify patients
98 admitted with CAM. The primary endpoint was incidence of all cause mortality due to CAM.
99 Secondary outcomes studied were need for mechanical ventilation and intensive care unit(ICU)
100 admission. Baseline and time dependent risk factors significantly associated with death due to
101 CAM were identified by Relative risk estimation.

102 **Results:** 59 patients were diagnosed with Mucormycosis at NHRC (58 ROCM, 1 Renal
103 (disseminated) mucormycosis). Median age of the cohort was 52(IQR: 41,61) years and it
104 included 20.3% females. Median duration from first positive COVID-19 RT PCR test to
105 diagnosis of Mucormycosis was 17(IQR: 12,22) days. 90% patients were diabetic with 30%
106 being newly diagnosed at the time of COVID-19 admission and 89% having uncontrolled sugar
107 level (HbA1c > 7%). All patients were prescribed steroids during treatment for COVID-19. 56%
108 patients were prescribed steroids for non-hypoxemic, mild COVID (irrational steroid therapy)
109 while in 9%, steroids were indicated but were prescribed in inappropriately high dose. Majority
110 of the patients were treated with a combination of surgical debridement(94%), intravenous
111 Amphotericin B(91%) and concomitant oral Posaconazole therapy(95.4%). 74.6% patients were
112 discharged after clinical and radiologic recovery while 25.4% (15 patients) died. On Relative risk
113 analysis, CT severity score during COVID-19 admission ≥ 18 ($p=0.017$), presence of orbital
114 symptoms($p=0.002$), presence of diabetic ketoacidosis($p=0.011$) and cerebral involvement by
115 Mucor($p=0.0004$) were associated with increased risk of death. Duration of Amphotericin B
116 therapy of ≥ 21 days was associated with statistically significant reduction in mortality($p=0.002$).

117 **Conclusions:** CAM is an uncommon, rapidly progressive, angioinvasive, opportunistic fungal
118 infection which is fatal if left untreated. Combination of surgical debridement and antifungal
119 therapy leads to clinical and radiologic improvement in majority of cases.

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143 **Introduction:**

144 In December 2019, Wuhan city, the capital of Hubei province in China, became the
145 centre of an outbreak of viral pneumonia. By Jan 7, 2020, scientists had isolated a novel RNA,
146 beta coronavirus from these patients. It was named severe acute respiratory syndrome
147 coronavirus 2 (SARS-CoV-2) due to its sequence homology with SARS-COV-1^[1]. The disease
148 caused by SARS-COV-2 was later designated coronavirus disease 2019 (COVID-19) in
149 February 2020, by World health organization (WHO)^[2]. COVID-19 spread rapidly worldwide
150 and India was no exception. By 1st August 2021, there have been more than 300 million
151 infections and 0.4 million deaths due to COVID-19 in India^[3]. With COVID-19, the incidence
152 of secondary bacterial or fungal infections is 8%, with aspergillosis and candida being the most
153 common fungi reported^[4,5]. The second COVID wave in India (March 2021 – May 2021),
154 triggered by the Delta variant, has also been associated with an unprecedented increase in the
155 cases of COVID-19 associated Mucormycosis (CAM)^[6,7]. Globally, the prevalence of
156 mucormycosis varies from 0.005 to 1.7 per million population, while its prevalence is nearly 80
157 times higher (0.14 per 1000) in India as per a recent estimate of year 2019-2020^[7-9]. Thus, India
158 already had the highest cases of mucormycosis in the world and the incidence increased
159 exponentially during the second COVID wave. As of August 1st, 2021, 45,374 cases of CAM
160 have been reported in India^[6].

161 CAM is an uncommon, rapidly progressive, angio-invasive, commonly fatal,
162 opportunistic fungal infection^[9]. Unusual alignment of multiple risk factors could be associated
163 with sudden spurt of CAM in India^[10]. Dysregulated immune response in COVID-19
164 characterized by exuberant activation of innate immune system, elevation in systemic
165 inflammatory markers (C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH) and D-
166 dimer), aberrant pro-inflammatory cytokine secretion (Interleukin – 6 (IL-6), soluble IL-2
167 receptor [IL-2R], IL-10, TNF- α) by alveolar macrophages and depleted adaptive immune
168 response (decline in CD4+ T cell, CD8+ T cell, Natural killer cell and decreased Interferon
169 Gamma (IFN- γ) expression in CD4+ T cells) could be one of the factors predisposing individuals
170 to CAM^[11,12]. In these patients, the activation of antiviral immunity to SARS-CoV-2 may,
171 paradoxically, potentiate an inflammatory phenotype and thus may favor secondary infections. In
172 addition, India has the second largest population with diabetes mellitus (DM) in the world (77

173 million people with diabetes, with a nationwide prevalence of 7.3 %.)^[13, 14]. SARS-CoV-2 has
174 been shown to affect the beta cells of the pancreas, resulting in metabolic derangement, possibly
175 causing diabetes mellitus ^[15]. Uncontrolled DM is a risk factor for both, COVID-19 and
176 Mucormycosis. Steroids, namely Dexamethasone and Methylprednisolone have been extensively
177 used to resolve hyperinflammation and inflammatory lung damage in severe COVID-19 ^[16-18].
178 But use of steroids can cause hyperglycemia, suppression of several polymorphonuclear (PMN)
179 leucocyte functions, impairment of phagocytosis by resident macrophages, depletion of T cell
180 immunity ^[10] and increase risk of Mucormycosis. Indiscriminate use of steroids in patients with
181 mild or asymptomatic COVID-19 can be counter-productive and make the person susceptible to
182 opportunistic fungi ^[19]. Use of immunomodulator therapy like Tocilizumab (TCZ, IL-6 receptor
183 inhibitor) in combination with steroids for Cytokine release syndrome (CRS, cytokine storm)
184 could further aggravate immunosuppression and facilitate breakthrough fungal infection ^[20].
185 Thus, the primary reason for this sudden increase in CAM in India appears to be germination of
186 Mucorales spores in an ideal environment of low oxygen (hypoxia), high glucose (diabetes
187 mellitus, new onset hyperglycemia, impaired fasting glucose or steroid-induced hyperglycemia),
188 acidic environment^[10] (metabolic acidosis, diabetic ketoacidosis [DKA]), high iron levels (hyper-
189 ferritinemia characteristic of COVID-19 leading to excess intracellular iron that generates
190 reactive oxygen species and resultant death of cells with acidosis facilitating free iron release for
191 mucor germination) ^[21,22] and immune dysfunction (mediated by Delta variant of SARS COV-2,
192 steroid therapy or background co-morbidities).

193 The most common form of Mucormycosis seen in India during the COVID-19 pandemic
194 was the Rhino-orbito-cerebral (ROCM) one but cases of pulmonary ^[7,23] or disseminated
195 mucormycosis ^[24] have also been reported. Suspected ROCM requires urgent intervention,
196 because of the often rapidly progressive and destructive nature of the infection. Delayed
197 initiation of therapy is associated with increased mortality ^[25,26]. Despite treatment, case-fatality
198 rates due to mucormycosis during the pre-COVID-19 pandemic era were already high, ranging
199 from 32% to 70%, according to organ involvement ^[25,26]. However, in SARS-CoV-2 infection,
200 the mortality maybe even higher. Maximizing survival rates requires rapid diagnostic and
201 therapeutic intervention, including immediate involvement of a multidisciplinary medical,
202 surgical, radiological, and laboratory-based team. Multiple case reports ^[27-50] and retrospective

203 cohort studies ^[7, 51-61] of CAM from India and other countries have already been published.
204 However, detailed epidemiology, risk factor analysis, surgical and medical treatment
205 administered, outcomes and complications (especially long-term complications) developing in
206 these patients has been scarcely reported ^[7,52,57]. In addition, lack of imaging modalities in rural
207 areas of India, inability to identify early symptoms by general practitioners, shortage of
208 antifungal drugs (especially Liposomal Amphotericin B) during second COVID wave and
209 inadequate number of specialists to perform complex endoscopic, orbital and skull base surgeries
210 ^[7,10] posed a serious challenge in tackling rising ROCM cases in India and led to a high mortality
211 in certain cohort studies ^[7,52]. As a result, we planned this retrospective observational cohort
212 study aimed at understanding the epidemiology, clinical presentation, outcomes and long-term
213 complications in patients with CAM admitted at our tertiary level hospital in Pune, Western
214 India during the COVID-19 pandemic.

215 **Methods:**

216 **Study Setting:**

217 This retrospective cohort study was conducted at Noble hospital and Research Centre
218 (NHRC), Pune, Western India. NHRC is a tertiary level private hospital designated for clinical
219 management of COVID-19 patients and management of post COVID complications since 23rd
220 March 2020. Pune is located in the state of Maharashtra, Western India and was one of the
221 epicenters of COVID-19 epidemic in India. As of 1st August 2021, Maharashtra state has
222 reported more than 6.3 million cases of COVID-19 and more than 133,000 deaths ^[3]. Till 1st
223 August 2021, NHRC has admitted 5439 COVID-19 patients with 391 deaths. Maharashtra state
224 has also reported more than 5000 cases of COVID-19 associated Mucormycosis (CAM) till 1st
225 August 2021^[6].

226 NHRC provides clinical care, diagnostic and treatment services to patients at a subsidized
227 cost. Data of all hospitalized patients is entered into an electronic database (Lifeline electronic
228 database, Manorama infosystems, Kolhapur, India).

229 **Study Population:**

230 Patients were eligible for inclusion in this analysis if they were admitted to NHRC
231 between 1st April 2020 and 1st August 2021 and were diagnosed with COVID-19 associated
232 Mucormycosis (CAM). COVID-19 diagnosis was made in patients who tested positive for SARS

233 COV 2 RNA in respiratory specimens by reverse transcription PCR (RT-PCR) or a positive rapid
234 antigen test. Mucormycosis was identified in patients having compatible clinical and radiologic
235 manifestations and demonstration of fungi in the tissue or sterile body fluids by either direct
236 microscopic visualization of broad ribbon-like aseptate hyphae (potassium hydroxide (KOH)
237 mount or Calcofluor stain) , culture isolation of Mucorales (Sabouraud dextrose agar) or
238 Histopathology examination of affected tissue showing Mucor species (Hematoxylin and eosin,
239 periodic acid Schiff, or Gomori methenamine silver stain) ^[9]. CAM was defined as development
240 of Mucormycosis within 3 months of diagnosis of COVID-19.

241 Data was obtained from electronic health record of each individual admitted for treatment
242 of CAM in NHRC by manual abstraction. It included hospitalization dates, demographics, co-
243 morbidities, severity of associated COVID-19 illness, treatment received for COVID-19
244 including steroids and immunomodulator therapy, presenting symptoms of Mucormycosis,
245 clinical examination data, anatomic site of involvement, diagnostic modalities including
246 microscopy, culture, or histopathology, laboratory investigation data (including inflammatory
247 markers), microbiology reports, imaging reports (High resolution computerized tomography scan
248 of chest, paranasal sinuses and brain (HRCT chest, CT PNS and CT brain)), treatment details,
249 including antifungal drug therapy and surgical debridement, data on use of supplemental oxygen,
250 mechanical ventilation and hospitalization outcomes. Mild COVID was defined as individuals
251 who have various signs and symptoms of COVID-19 but who do not have shortness of breath,
252 dyspnea, or abnormal chest imaging ^[62]. Moderate disease was defined as patients who show
253 evidence of lower respiratory disease during clinical assessment or imaging and who have
254 oxygen saturation (SpO₂) 90 to ≤ 93% on room air. Severe COVID was defined as SpO₂ < 90%
255 on room air, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen
256 (PaO₂/FiO₂) < 300 mm Hg, respiratory frequency > 30 breaths/min or lung infiltrates >50% ^[62].
257 Critical COVID was defined as presentation with respiratory failure, septic shock, and/or
258 multiple organ dysfunction. For all patients diagnosed with CAM, we also scrutinized inpatient
259 case files until hospital discharge, death, or 1st September 2021—the date on which the database
260 was locked—whichever happened first. Systemic complications developing in patients during
261 hospital admission were also noted. All patients who died due to CAM during hospital admission
262 were identified and a death audit to look for complications and cause of death was undertaken.

263 For patients who left the hospital against medical advice, we considered a worst-case scenario
264 for mortality analysis and assumed the patients died. All patients who recovered, got discharged
265 from NHRC and had outpatient follow-up at 15, 30 and 90 days after discharge were identified.
266 Their outpatient follow-up visits were traced from electronic database to look for delayed
267 complications.

268 **Management of Mucormycosis at NHRC:**

269 NHRC protocol for management of Mucormycosis has been developed after careful
270 consideration of current global and national guidelines ^[63,64]. As per the protocol, early, radical,
271 surgical debridement of affected site in addition to combination systemic antifungal therapy was
272 utilized for treatment.

273 **Surgical management:**

274 Functional endoscopic paranasal sinus surgery (FESS) with debridement of necrosed and
275 diseased sinus tissue and orbital decompression was the most common surgical procedure
276 performed in patients with ROCM. All efforts were made to preserve the eye for as long as
277 possible in view of role of eye to not only provide vision but also its removal causing significant
278 psycho-social problems to patient. In patients with total blindness, proptosis, fixed pupil and
279 eyeball, imaging evidence of orbital involvement by Mucor (globe/muscles/fat) and/or
280 intracranial spread (superior orbital fissure/inferior orbital fissure involvement), surgical
281 exenteration of the eye was performed ^[65]. Surgical exenteration of the eye with debridement of
282 orbital cavity was performed in consultation with Department of Otorhinolaryngology and
283 Ophthalmology. Partial or total maxillectomy was performed in patients with evidence of
284 osteomyelitis of maxilla or alveolar arch. Neurosurgery was performed in case of intracranial
285 spread of disease with involvement of skull base or formation of basi-frontal lobe brain abscess.

286 **Medical management:**

287 Combination therapy of Liposomal Amphotericin B (LAmB) and Oral Triazole
288 (predominantly oral Posaconazole) was the most common medical treatment offered to all
289 patients with CAM. LAmB was initiated at the dose of 5 mg/kg. The dose was increased to 10
290 mg/kg in case of intracranial spread ^[63,64]. In the scenario of shortage of LAmB due to surge in
291 CAM cases or non affordability of patient, other formulations of Amphotericin B (Amphotericin
292 B lipid complex (5 mg/kg), Amphotericin B lipid emulsion (5 mg/kg) and Amphotericin B de-

293 oxycholate (1 mg/kg)) were used for patients. The duration of Amphotericin B treatment was
294 decided depending on the site of involvement (3 weeks for only paranasal sinus involvement, 4
295 weeks for orbital, lung and disseminated Mucormycosis and 6 weeks for Central nervous system
296 (CNS) Mucormycosis). Oral Posaconazole (delayed release tablets, 300 mg twice a day on Day 1
297 and then 300 mg once a day) was started along with Amphotericin B treatment and continued
298 after discharge from hospital for a period of 1 to 3 months depending on local control of disease
299 and discretion of Infectious disease physician. In patients with concomitant chronic kidney
300 disease, intravenous Posaconazole or Isavuconazole followed by step-down to oral therapy was
301 treatment of choice. Serum Posaconazole levels were performed to guide dosage during oral
302 therapy.

303 **Outcomes:**

304 Primary endpoint:

305 1) Deaths in the cohort due to CAM.

306 Secondary outcomes:

307 2) Number of patients who had a clinical and radiologic recovery and were discharged from
308 hospital.

309 3) Patients who required mechanical ventilation (noninvasive or invasive) and Intensive care
310 unit (ICU) admission for CAM.

311 4) Incidence of systemic complications (including long-term complications) in patients after
312 starting Amphotericin B therapy.

313 The use of database for clinical research was approved by the institutional review board
314 (IRB) of Noble hospital and Research Centre, Pune, India.

315 **Statistical Methods:**

316 Continuous variables were summarized using median and interquartile range (IQR),
317 while categorical variables were summarized using frequency and percentages. Continuous
318 variables were compared using a Mann Whitney U test. Categorical variables were compared
319 using Chi-square test, Proportion test and Fishers' exact test. Baseline and time dependent risk
320 factors significantly associated with death due to CAM were identified by Relative risk analysis.
321 Baseline risk factors included for analysis were age (< 60 years or \geq 60 years), gender, severity of
322 baseline COVID disease (CT severity index \geq 18 versus < 18), presence of orbital or central

323 nervous system (CNS) symptoms, presence of diabetic keto-acidosis, presence of intracranial
324 spread (cerebral involvement) and baseline investigations like absolute lymphocyte count (<
325 1000 versus \geq 1000 cells/mm³), C reactive protein (\geq 50 versus < 50 mg/L), D-dimer (\geq 252
326 versus < 252 mcg/mL) and Ferritin (\geq 1000 versus < 1000 mcg/L). Time dependent risk factors
327 included duration of Amphotericin B therapy (< 3 weeks versus \geq 3 weeks) and development of
328 systemic complications like acute kidney injury, hepatitis, anemia, thrombocytopenia,
329 osteomyelitis and CNS complications (stroke or cerebritis). The p value \leq 0.05 was considered as
330 statistically significant. All data was analyzed by SPSS version 12.0.

331 **Results:**

332 During the period between 1st April 2020 to 1st August 2021, 59 patients were diagnosed
333 with Mucormycosis at NHRC. Fifty-eight patients were diagnosed to have ROCM while 1
334 patient was diagnosed to have Renal (disseminated) mucormycosis. Median age of the cohort
335 was 52 (IQR: 41, 61) years and it included 20.3 % (12/59) females. Seventeen (28.8 %) patients
336 were > 60 years of age. Fifty-six (95 %) patients had pre-existing or newly diagnosed co-
337 morbidities. Diabetes mellitus (53/59, 89.8 %) was the most common co-morbidity seen in our
338 cohort. Of these, 15 patients (28.3 %) were newly diagnosed with diabetes during hospital
339 admission for COVID-19. Two patients were diagnosed to have impaired fasting glucose
340 (Fasting blood glucose between 110 and 125 mg/dl). Preexisting co-morbidities observed in
341 patients at admission are enumerated in Table 1. Three patients (5.1%) had no co-morbidities
342 prior to developing CAM.

343 Clinically, 16 patients (27.1%) had mild COVID, 29 (49.2 %) had moderate COVID and
344 14 patients (23.7%) had severe or critical COVID disease prior to diagnosis of Mucormycosis.
345 All 59 patients underwent High resolution CT (HRCT) imaging of chest (GE Optima, 128 slice
346 CT scanner) during admission for COVID-19 and median CT severity index was 12 (IQR:
347 8,14.5). CT severity index ^[66] indicated mild disease (CT severity index: < 8) in 18.6 % (11/59),
348 moderate disease (CT severity index: 8-14) in 56 % (33/59) and severe disease (CT severity
349 index: 15-25) in 25.4 % (15/59) of patients. Treatments given during COVID-19 admission are
350 enumerated in Table 2a and 2b. Remdesivir was prescribed to 67.8 % (40/59), intravenous and/or
351 oral steroids were prescribed to 100 % and Immune-modulator therapy (Tocilizumab - 5,
352 Baricitinib-2, Idofinib- 1, Infliximab- 2, Bevacizumab - 2 and Itolizumab - 1) was prescribed to

353 22 % (13/59) patients in our cohort. Methylprednisolone was the commonest prescribed steroid
354 (54 patients, 91.5%, Table 2b). Most commonly prescribed dose of Methylprednisolone was 1-2
355 mg/kg/day in divided doses for 5 to 10 days ^[67]. Ten patients (16.9 %) were prescribed 2
356 different steroids during treatment course for COVID-19. 56 % (33/59) patients were prescribed
357 steroids in the absence of hypoxia (irrational or unscientific steroid use). In 5 (5/54, 9.3%)
358 patients, Methylprednisolone dose of more than 2 mg/kg/day was prescribed for treatment of
359 severe COVID-19 (wrong or excess steroid dose). Eleven patients (18.6%) required ICU
360 admission while 7 (11.9 %) needed noninvasive or invasive ventilation during hospital admission
361 of COVID-19 infection. Thirteen patients (22%) had received COVID vaccination prior to
362 admission (3 patients received 2 vaccine doses and 10 patients received single vaccine dose,
363 Table 1). Five patients (8.5 %) were treated for COVID-19 while in home quarantine and did not
364 require hospital admission. All 5 patients in home quarantine received steroids (irrational or
365 unscientific steroid use) as a part for of their treatment regimen. Median duration of hospital
366 admission for COVID-19 was 9 (IQR: 6, 14) days.

367 Median duration from first positive COVID-19 RT PCR test to diagnosis of
368 Mucormycosis was 17 (IQR: 12, 22) days. Duration was less than 14 days for 22 (37.3 %, early
369 CAM) patients while it was > 14 days for 37 (62.7 %, late CAM) patients. Median duration
370 between hospital discharge for COVID-19 to re-admission for Mucormycosis was 7 (IQR: 2.5,
371 15.5) days. Twenty patients (33.9 %) were diagnosed to have Mucormycosis (suspected fungal
372 sinusitis, ROCM) during admission for COVID-19. Twenty-seven (45.7 %) were re-admitted
373 less than 14 days after hospital discharge for COVID-19 while 12 (20.4 %) were re-admitted
374 after more than 14 days. Headache (43/58, 74.1 %), hemi-facial pain predominantly maxillary
375 pain (42/58, 72.4 %) and facial swelling (33/58, 56.9 %) were the three commonest presenting
376 symptoms of ROCM in our cohort (Table 3). Median duration of symptoms was 6 (IQR: 3, 8.5)
377 days. Seven patients (11.9 %) had symptoms for more than 2 weeks prior to diagnosis of ROCM.
378 Fifty-eight patients (99%) had rhinal (paranasal sinus) involvement, 33 (56%) had orbital
379 (eyeball, extra-ocular muscles or orbital cavity) and 26 (44.1%) had cerebral involvement
380 (infarcts, cavernous sinus involvement, dural enhancement, frontal lobe abscess, osteomyelitis
381 and erosion of frontal bone, Table 3). Palatal involvement (palatal necrosis, black eschar or
382 palatal osteomyelitis) was observed in 13 (22 %) patients. Median hemoglobin value at diagnosis

383 of Mucormycosis was 13.4 (IQR: 11.4, 14.5) mg/dl (Table 4). Median absolute neutrophil count
384 (ANC) was 8100 (IQR: 5248, 11475) cells/mm³ and median absolute lymphocyte count (ALC)
385 was 1350 (IQR: 1010, 1750) cells/mm³. Fourteen patients (24.6 %) had ALC < 1000 cells/mm³
386 while no patient had ANC < 1000 cells/mm³ at admission. Median CRP at admission was 84.7
387 (IQR: 41,167, 45 patients) mg/L, median D-dimer was 483.5 (IQR: 253.7,1201, 37 patients)
388 mcg/mL, and median Ferritin value was 857.1 (IQR: 280.5, 1429, 32 patients) mcg/L. Thirteen
389 patients (40.6 %) had serum Ferritin level > 1000 mcg/L at admission while 11 patients had D-
390 dimer > 1000 mcg/mL. Median HbA1C level in our cohort was 9.3 (IQR: 8, 12). Ten patients
391 (10/53, 18.9%) presented with diabetic ketoacidosis. Diagnosis of Mucormycosis was made by
392 KOH/calcofluor white staining of nasal scrapings (25/59, 42.4%), culture (5/59, 8.5%) and
393 histopathologic examination of excised tissue from paranasal sinuses (57/59, 96.6%). Mixed
394 mould infection (mucormycosis and aspergillosis) was observed in 3 patients.

395 Aggressive surgical debridement of involved site and combination antifungal therapy was
396 standard of care for all ROCM patients in our cohort. Empirical combination anti-fungal therapy
397 was started after radiologic evidence of invasive sinusitis, pending confirmatory diagnosis by
398 histopathology or culture. Various treatment modalities used in our cohort are mentioned in
399 Table 5. Intravenous (IV) formulations of Amphotericin B (Liposomal, Lipid-complex, Lipid
400 emulsion or Deoxycholate) were the mainstay of antifungal therapy and prescribed to 91.5%
401 (54/59) patients. In view of shortage of Liposomal Amphotericin B in India during the second
402 COVID-19 wave, patients ended up getting a combination of Amphotericin B formulations as
403 per availability. Liposomal Amphotericin B was prescribed to 89.8 % (53/59) patients for a
404 median duration of 15 (IQR: 11, 21) days. Amphotericin B de-oxycholate or Conventional
405 Amphotericin B was prescribed to 45.8% (27/59) patients for a median duration of 4 (IQR: 3, 9)
406 days. The median duration of Amphotericin B exposure to patients in our cohort was 21 (IQR:
407 14, 27) days. All patients were also prescribed concomitant oral triazole therapy (Posaconazole
408 (58/59, 98.3%) or Isavuconazole (5/59, 8.5%)) during admission and after discharge till clinician
409 was satisfied about local control of disease. Median duration for oral triazole therapy was 60
410 days. FESS with orbital decompression was performed on 94.9 % patients (56/59). Surgical
411 exenteration of the eye with debridement of orbital cavity was performed in 13 (22 %) patients.
412 Partial maxillectomy was performed in 9 (15.3 %) patients while Neurosurgery for frontal lobe

413 brain abscess drainage was performed in 5 (8.5 %) patients. Eight patients (13.6 %) required
414 invasive mechanical ventilation while 18 (30.5 %) required ICU admission for Mucormycosis.

415 Complications during antifungal therapy and hospital admission are mentioned in Table
416 6. Fever with chills (78 %), Thrombophlebitis (59.3 %), Hypokalemia (88.1 %), Anemia (57.6
417 %) and Nephrotoxicity (50.8 %) were the most common complications observed during hospital
418 admission. Central nervous system (CNS) complications (stroke/cerebritis/brain abscess) were
419 seen in 25.4 % patients. There were 14 deaths (23.7 %) in our cohort during first hospital
420 admission for Mucormycosis. On Relative risk analysis, CT severity score during COVID-19
421 admission ≥ 18 ($p = 0.017$), presence of symptoms like eye swelling ($p = 0.002$), loss of vision (p
422 < 0.0001), ptosis ($p = 0.005$) and limb weakness ($p = 0.001$), presence of diabetic ketoacidosis (p
423 $= 0.011$), cerebral involvement by Mucor ($p = 0.0004$) and development of CNS complications
424 like stroke ($p < 0.0001$) during antifungal therapy were associated with increased risk of death
425 (Table 7, Figure 1). Duration of Amphotericin B treatment of more than 21 days was associated
426 with decreased risk of death ($p = 0.002$) on Relative risk analysis (Table 7). All patients who
427 were discharged from hospital were followed up for a minimum period of 6 weeks to look for
428 late complications. Three patients needed re-admission, 48, 54 and 37 days after first discharge
429 in view of re-appearance of symptoms and/or imaging evidence of progression of disease to the
430 CNS. All 3 patients needed repeat surgical debridement and additional Amphotericin B
431 treatment. They were successfully discharged the second time. Two patients also needed re-
432 admission for osteomyelitis of maxilla and alveolar arch which needed partial maxillectomy and
433 placement of dental prosthesis. One patient who had undergone exentration of eye was
434 readmitted 90 days later for insertion of orbital prosthesis. One patient who had been treated for
435 cerebral mucormycosis (bilateral complete vision loss and multiple cerebral infarcts) with 42
436 days of high dose Liposomal Amphotericin B and Posaconazole was readmitted with aspiration
437 pneumonia 12 days later and died. Cause of death was respiratory failure due to aspiration
438 pneumonia and acute respiratory distress syndrome (ARDS, Total deaths in cohort - 15, 25.4%).

439 **Discussion:**

440 We conducted a single-centre, retrospective cohort study of 59 patients with CAM who
441 were admitted at NHRC in the last 15 months. 74.6% patients could be successfully discharged

442 after control of disease with combined surgical and medical approach. Mortality rate in our
443 cohort at 6 weeks follow-up was 25.4 %.

444 Majority of the patients in our study were middle-aged (median age: 52□years), of which
445 nearly two-thirds were male. It has been hypothesized that the effect of estrogen might be
446 protective in systemic fungal infection, which could have led to lower incidence in females ^[68].
447 Case series on CAM by Sharma et al ^[46], described diabetes as a risk factor in 90% cases of
448 which 52% had uncontrolled disease. A systematic review of 101 cases of CAM by Singh et al
449 ^[58] also noted that more than 80% cases had either pre-existing or new onset hyperglycaemia as a
450 risk factor. Our study has demonstrated similar findings in that 90 % of included patients were
451 diabetic with almost 30% being newly diagnosed with DM at the time of admission for COVID-
452 19. Of the 56 patients who had HbA1c value available, 50 had uncontrolled DM (HbA1c > 7%).
453 Median HbA1c in our cohort was 9.3% while it was 9.6% in the study by Sen et al ^[55]. Tight
454 control of blood sugar level among patients with Diabetes Mellitus/ COVID-19 co-infection
455 could help in reducing incidence of ROCM.

456 Both the RECOVERY trial ^[17] and WHO COVID-19 ^[69] guidelines clearly recommend
457 against usage of Corticosteroids in COVID-19 patients not requiring oxygen (absence of
458 hypoxia). Despite that, indiscriminate use of steroids in mild COVID-19 continues in India. The
459 underlying reasons include the sudden surge of cases during second COVID wave leading to
460 panic among general practitioners, inadequate time for triaging patients in busy outpatient
461 clinics, non evidence-based clinical practice, availability of over the counter steroids, shortage of
462 hospital beds and inadequate monitoring of the patients taking steroids. The improper use of
463 corticosteroids has been identified as an independent risk factor for CAM by the MucoCovi
464 network ^[7]. In their retrospective analysis of 187 Indian CAM patients, they found that 78%
465 (150/187) had received steroid therapy but only 33% patients had received steroids at appropriate
466 dosages. In 33 % patients (50/150), steroids were not indicated while among 30% (45/150)
467 patients steroids were indicated but were prescribed in inappropriately high dose ^[7]. In
468 comparison, in our study, 56 % patients were prescribed steroids for non-hypoxemic, mild to
469 moderate COVID illness (irrational steroid therapy) while in 8.5 % patients steroids were
470 indicated but were prescribed in inappropriately high dose. Thus there is an urgent need to stop

471 prescription of steroids in non-hypoxemic COVID-19 patients and to limit the dose and duration
472 of steroids in hypoxic patients.

473 In our cohort, majority of the patients were treated with a combination of surgical
474 debridement (94%) and intravenous Amphotericin B therapy (91%). Mortality rate at 6 weeks
475 follow-up was 25.4 % which is lower than what is reported by Pal et al ^[57] and Patel et al
476 (MucoCovi network - 6 week mortality rate of 38.3 % and 12 week mortality of 45.7 %) ^[7].
477 Reasons for lower mortality in our cohort as compared to the MucoCovi network ^[7] could be
478 relatively younger population (median age 52 years versus 56.9 years), lower prevalence of
479 hypoxia during COVID-19 (44 % versus 56 %), lower pulmonary involvement due to
480 Mucormycosis (0 % versus 8.6 %), increased use of combination antifungal therapy (91% versus
481 50%) and higher use of combined surgical and medical approach (91% versus 71%). However,
482 presence of diabetic ketoacidosis (10.9 % versus 8.6 %) and prevalence of cerebral involvement
483 due to Mucor (44 % versus 23 %) was higher in our cohort than the MucoCovi study ^[7]. Both the
484 factors, presence of diabetic ketoacidosis ($p = 0.011$) and cerebral involvement with Mucor ($p =$
485 0.0004) were associated with higher risk of mortality on Relative risk analysis. In patients with
486 cerebral involvement due to Mucor, mortality rate was 50% which is 5 times higher than among
487 patients without cerebral involvement. On the other hand, duration of Amphotericin B therapy of
488 more than 21 days was associated with statistically significant reduction in mortality ($p = 0.002$).
489 Development of ROCM while the patient is still under active treatment for moderate or severe
490 COVID-19 may pose significant challenges in the management – specifically termination of
491 corticosteroids, and surgery under general anesthesia. This was reflected in the CT severity index
492 > 18 (depicting severe COVID pneumonia) being a significant risk factor for increased risk of
493 death due to CAM ($p = 0.017$). Patients with ROCM also remain at risk for delayed
494 complications and may need re-admission with further surgical and anti-fungal treatment to
495 resolve them.

496 **Limitations:**

497 Our study has several limitations. First, this is not a randomized controlled trial, and
498 therefore unmeasured confounding cannot be ruled out. Second, as for all retrospective studies,
499 some individuals diagnosed with Mucormycosis may be unreported leading to measurement bias
500 and underestimation of mortality due to CAM. Third, we collected data from a single centre in

501 India unlike other multicenter cohort studies [7, 52,54,55,57]. Fourth, an overwhelmed health care
502 system, inadequate workforce and lack of exhaustive reporting due to surge of cases during
503 second COVID wave could be responsible for underestimation of co-morbidities, presenting
504 symptoms and complications amongst patients in our cohort. Fifth, inflammatory markers like
505 Ferritin, CRP and D-dimer were not available for all patients in the cohort. Sixth, we did not look
506 for environmental factors causing healthcare-associated mucormycosis like contaminated
507 ventilation systems, air conditioners, and ongoing construction in our hospital. We did not
508 estimate the burden of Mucormycetes spores in our hospital environment. We also didn't
509 investigate the link between risk factors like use of industrial oxygen during the COVID
510 pandemic, contaminated nebulizer fluids or inline humidifier tubing used in ventilator circuits
511 and contaminated oxygen delivery systems with increased incidence of CAM in our cohort [10].
512 Seventh, other unexplored factors, including genetic predisposition were not identified.

513 Despite these limitations, this retrospective cohort study adds to the growing body of
514 literature on epidemiology, management strategies, outcomes and long term complications due to
515 COVID-19 associated Mucormycosis (CAM).

516 **Conclusions:**

517 COVID-19 associated Mucormycosis (CAM) is an uncommon, rapidly progressive,
518 angio-invasive, opportunistic fungal infection which is fatal if left untreated. The most common
519 form of CAM seen in our cohort was the Rhino-orbito-cerebral (ROCM) one. COVID-19
520 induced immune dysregulation, uncontrolled diabetes mellitus and indiscriminate use of steroids
521 may be the risk factors associated with the sudden surge in Mucormycosis cases in India during
522 the second wave. Clinicians should have a high index of suspicion for ROCM in patients
523 recovering from COVID-19, especially among patients with new or previously diagnosed
524 diabetes mellitus and clinical manifestations of headache, facial or orbital pain. Combination of
525 surgical debridement and intravenous Amphotericin B therapy leads to clinical and radiologic
526 improvement in majority of cases. Cerebral involvement by Mucor is associated with higher
527 mortality.

528 **Acknowledgements:**

529 Manisha Ghate MD, PhD (National AIDS Research Institute (NARI), Pune, India) - edited the
530 manuscript.

531 **References:**

532 1) Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus
533 disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from
534 the Chinese Center for Disease Control and Prevention. *JAMA*. 2020.
535 <https://doi.org/10.1001/jama.2020.2648>

536 2) World health organization (WHO): Available at
537 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)
538 [guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it).

539 3) World health organization (WHO) Coronavirus disease (COVID-19) dashboard.
540 Available at: <https://covid19.who.int>.

541 4) Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M et al.
542 Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To
543 Support COVID-19 Antimicrobial Prescribing. *Clin Infect Dis*. 2020 Dec 3; 71(9):2459-
544 2468. doi: 10.1093/cid/ciaa530. PMID: 32358954; PMCID: PMC7197596.

545 5) Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19
546 Pandemic: A Clinical and Diagnostic Perspective from China. *Mycopathologia*. 2020
547 Aug; 185(4):599-606. doi: 10.1007/s11046-020-00462-9. Epub 2020 Jul 31. PMID:
548 32737747; PMCID: PMC7394275.

549 6) Press release from Government of India at
550 <https://pib.gov.in/PressReleasePage.aspx?PRID=1728153> accessed July 21st, 2021.

551 7) Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R et al; MucoCovi
552 Network3. Multicenter Epidemiologic Study of Coronavirus Disease-Associated
553 Mucormycosis, India. *Emerg Infect Dis*. 2021 Jun 4; 27 (9). doi:
554 10.3201/eid2709.210934. Epub ahead of print. PMID: 34087089.

555 8) Chakrabarti A, Kaur H, Savio J, Rudramurthy SM, Patel A, Shastri P et al. Epidemiology
556 and clinical outcomes of invasive mould infections in Indian intensive care units (FISF

- 557 study). *J Crit Care*. 2019 Jun;51 :64-70. doi: 10.1016/j.jcrc.2019.02.005. Epub 2019 Feb
558 5. PMID: 30769292.
- 559 9) Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. *J Fungi (Basel)*. 2019
560 Mar 21; 5(1):26.
- 561 10) Narayanan S, Chua JV, Baddley JW. COVID-19 associated Mucormycosis (CAM): risk
562 factors and mechanisms of disease. *Clin Infect Dis*. 2021 Aug 22:ciab726. doi:
563 10.1093/cid/ciab726. Epub ahead of print. PMID: 34420052.
- 564 11) García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19.
565 *Front Immunol*. 2020 Jun 16; 11: 1441. <https://doi.org/10.3389/fimmu.2020.01441>
- 566 12) Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in
567 COVID-19: addressing a pharmacological challenge by targeting pathways triggered by
568 SARS-CoV-2. *Signal Transduct Target Ther*. 2020 May 29; 5(1):84.
569 <https://doi.org/10.1038/s41392-020-0191-1>
- 570 13) IDF Diabetes ATLAS Ninth Edition. 2019. [https://diabetesatlas.org/upload/resources/
571 material/20200302_133351_IDFAT_LAS9e_final_web.pdf#page=42&zoom=auto](https://diabetesatlas.org/upload/resources/material/20200302_133351_IDFAT_LAS9e_final_web.pdf#page=42&zoom=auto).
572 Accessed May 12, 2020.
- 573 14) Anjana RM, Deepa M, Pradeepa R, et al. Prevalence of diabetes and prediabetes in 15
574 states : results from the ICMR–INDIAB population-based cross-sectional study. *Lancet
575 Diabetes Endocrinol*.2017;5: 585-596.
- 576 15) Müller JA, Groß R, Conzelmann C, et al. SARS-CoV- 2 infects and replicates in cells of
577 the human endocrine and exocrine pancreas. *Nat Metab*. 2021; 3: 149-165.
578 <https://doi.org/10.1038/s42255-021-00347-1>.
- 579 16) WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group,
580 Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC et al. Association
581 Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill
582 Patients With COVID-19: A Meta-analysis. *JAMA*. 2020 Oct 6; 324(13):1330-1341.
583 <https://doi.org/10.1001/jama.2020.17023>
- 584 17) RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell
585 JL, Linsell L et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary

- 586 Report. *N Engl J Med.* 2020 Jul 17: NEJMoa2021436.
587 <https://doi.org/10.1056/NEJMoa2021436>
- 588 18) Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. *Lancet.*
589 2003 Nov 29;362(9398):1828-38. doi: 10.1016/S0140-6736(03)14904-5. PMID:
590 14654323.
- 591 19) Rodriguez-Morales AJ, Sah R, Millan-Oñate J, Gonzalez A, Montenegro-Idrogo JJ,
592 Scherger S et al. COVID-19 associated mucormycosis: the urgent need to reconsider the
593 indiscriminate use of immunosuppressive drugs. *Ther Adv Infect Dis.* 2021 Jun 18;8:
594 20499361211027065. doi: 10.1177/20499361211027065. PMID: 34211710; PMCID:
595 PMC8216396.
- 596 20) Actemra (tocilizumab) Prescribing information. South San Francisco, CA: Genentech,
597 Inc; 2019.
- 598 21) Ibrahim AS, Spellberg B, Edwards J. Iron acquisition: a novel perspective on
599 mucormycosis pathogenesis and treatment. *Curr Opin Infect Dis.* 2008; 21: 620-625.
600 <https://doi.org/10.1097/QCO.0b013e3283165fd1>
- 601 22) Perricone C, Bartoloni E, Bursi R, et al. COVID-19 as part of the hyperferritinemic
602 syndromes: the role of iron depletion therapy. *Immunol Res.* 2020; 68 : 213-224.
603 <https://doi.org/10.1007/s12026-020-09145-5>.
- 604 23) Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, Simeo R, Buselli A,
605 Rizzo D, Bussu F, Rubino S, Terragni P. A challenging complication following SARS-
606 CoV-2 infection: a case of pulmonary mucormycosis. *Infection.* 2020 Dec 17:1–6. doi:
607 10.1007/s15010-020-01561-x. Epub ahead of print. PMID: 33331988; PMCID:
608 PMC7745708.
- 609 24) Monte Junior ESD, Santos M, Ribeiro IB, et al. Rare and fatal gastrointestinal
610 mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. *Clin Endosc* 2020;
611 53: 746–749.
- 612 25) Deutsch P.G., Whittaker J., Prasad S. Invasive and non-invasive fungal rhinosinusitis—a
613 review and update of the evidence. *Medicina.* 2019;55: 1–14.

- 614 26) Brunet K and Rammaert B. Mucormycosis treatment: recommendations, latest advances,
615 and perspectives. *J Mycol Med* 2020; 30: 101007.
- 616 27) Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, Puri GD, Chakrabarti
617 A, Agarwal R. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case
618 Report and Systematic Review of Literature. *Mycopathologia*. 2021 May;186(2):289-
619 298. doi: 10.1007/s11046-021-00528-2. Epub 2021 Feb 5. PMID: 33544266; PMCID:
620 PMC7862973.
- 621 28) Baskar HC, Chandran A, Reddy CS, Singh S. Rhino-orbital mucormycosis in a COVID-
622 19 patient. *BMJ Case Rep*. 2021 Jun 24;14(6):e244232. doi: 10.1136/bcr-2021-244232.
623 PMID: 34167998; PMCID: PMC8230977.
- 624 29) Rao R, Shetty AP, Nagesh CP. Orbital infarction syndrome secondary to rhino-orbital
625 mucormycosis in a case of COVID-19: Clinico-radiological features. *Indian J*
626 *Ophthalmol*. 2021 Jun;69(6):1627-1630. doi: 10.4103/ijo.IJO_1053_21. PMID:
627 34011758.
- 628 30) Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a
629 patient with COVID-19. *Am J Emerg Med* 2021; 42: 264. e5–264.e8.
- 630 31) Placik DA, Taylor WL and Wnuk NM. Bronchopleural fistula development in the
631 setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2
632 pneumonia. *Radiol Case Rep* 2020; 15: 2378–2381.
- 633 32) Kanwar A, Jordan A, Olewiler S, et al. A fatal case of *Rhizopus azygosporus* pneumonia
634 following COVID-19. *J Fungi (Basel)* 2021; 7: 174.
- 635 33) Dallalzadeh LO, Ozzello DJ, Liu CY, et al. Secondary infection with rhino-orbital
636 cerebral mucormycosis associated with COVID-19. *Orbit*. Epub ahead of print 23 March
637 2021. DOI: 10.1080/01676830.2021.1903044.
- 638 34) Johnson AK, Ghazarian Z, Cendrowski KD, et al. Pulmonary aspergillosis and
639 mucormycosis in a patient with COVID-19. *Med Mycol Case Rep* 2021; 32: 64–67.
- 640 35) Zurl C, Hoenigl M, Schulz E, et al. Autopsy proven pulmonary mucormycosis due to
641 *Rhizopus microsporus* in a critically ill COVID-19 patient with underlying
642 hematological malignancy. *J Fungi (Basel)* 2021; 7: 88.

- 643 36) Khatri A, Chang KM, Berlinrut I, et al. Mucormycosis after coronavirus disease 2019
644 infection in a heart transplant recipient – case report and review of literature. *J Mycol*
645 *Med* 2021; 31: 101125.
- 646 37) Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-
647 Gutierrez L. A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset
648 Diabetic Ketoacidosis and COVID-19. *Cureus*. 2021 Feb 5;13(2):e13163. doi:
649 10.7759/cureus.13163. PMID: 33575155; PMCID: PMC7870113.
- 650 38) Bellanger AP, Navellou JC, Lepiller Q, et al. Mixed mold infection with *Aspergillus*
651 *fumigatus* and *Rhizopus microsporus* in a severe acute respiratory syndrome
652 Coronavirus 2 (SARSCoV-2) patient. *Infect Dis Now*. Epub ahead of print 27 January
653 2021. DOI: 10.1016/j. idnow.2021.01.010.
- 654 39) Ahmadikia K, Hashemi SJ, Khodavaisy S, et al. The double-edged sword of systemic
655 corticosteroid therapy in viral pneumonia: a case report and comparative review of
656 influenza associated mucormycosis versus COVID-19 associated mucormycosis.
657 *Mycoses*. Epub ahead of print 16 February 2021. DOI: 10.1111/ myc.13256.
- 658 40) Karimi-Galougahi M, Arastou S and Haseli S. Fulminant mucormycosis complicating
659 coronavirus disease 2019 (COVID-19). *Int Forum Allergy Rhinol*. Epub ahead of print
660 13 March 2021. DOI: 10.1002/alr.22785.
- 661 41) Veisi A, Bagheri A, Eshaghi M, et al. Rhinorbital mucormycosis during steroid therapy
662 in COVID-19 patients: a case report. *Eur J Ophthalmol*. Epub ahead of print 10 April
663 2021. DOI: 10.1177/11206721211009450.
- 664 42) Meshram HS, Kute VB, Chauhan S, Desai S. Mucormycosis in post-COVID-19 renal
665 transplant patients: A lethal complication in follow-up. *Transpl Infect Dis*. 2021. June
666 3:e13663. <https://doi.org/10.1111/tid.13663> 10.1111/tid.13663 PMid: ;PMCID: . - DOI-
667 PMC - PubMed
- 668 43) Mehta S and Pandey A. Rhino-orbital mucormycosis associated with COVID-19.
669 *Cureus* 2020; 12: e10726.
- 670 44) Sen M, Lahane S, Lahane TP, et al. *Mucor* in a viral land: a tale of two pathogens.
671 *Indian J Ophthalmol* 2021; 69: 244–252.

- 672 45) Sarkar S, Gokhale T, Choudhury SS, et al. COVID-19 and orbital mucormycosis. *Indian*
673 *J Ophthalmol* 2021; 69: 1002–1004.
- 674 46) Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease
675 mucormycosis: a deadly addition to the pandemic spectrum. *J Laryngol Otol*. Epub
676 ahead of print 8 April 2021. DOI: 10.1017/S0022215121000992.
- 677 47) Saldanha M, Reddy R, Vincent MJ. Paranasal mucormycosis in COVID-19 patient.
678 *Indian J Otolaryngol Head Neck Surg*. Epub ahead of print 22 April 2021. doi:
679 10.1007/s12070-021-02574-0.
- 680 48) Revannavar SM, Supriya PS, Samaga L, et al. COVID-19 triggering mucormycosis in a
681 susceptible patient: a new phenomenon in the developing world? *BMJ Case Rep* 2021;
682 14: e241663.
- 683 49) Maini A, Tomar G, Khanna D, et al. Sino-orbital mucormycosis in a COVID-19 patient:
684 a case report. *Int J Surg Case Rep* 2021; 82: 105957.
- 685 50) Krishna V, Morjaria J, Jalandari R, Omar F, Kaul S. Autoptic identification of
686 disseminated mucormycosis in a young male presenting with cerebrovascular event,
687 multi-organ dysfunction and COVID-19 infection. *IDCases*. 2021;25:e01172. doi:
688 10.1016/j.idcr.2021.e01172. Epub 2021 May 28. PMID: 34075329; PMCID:
689 PMC8161734.
- 690 51) Ravani SA, Agrawal GA, Leuva PA, et al. Rise of the phoenix: mucormycosis in
691 COVID-19 times. *Indian J Ophthalmol* 2021; 69: 1563–1568
- 692 52) Selarka L, Sharma S, Saini D, Sharma S, Batra A, Waghmare VT et al. Mucormycosis
693 and COVID-19: An epidemic within a pandemic in India. *Mycoses*. 2021 Jul 13. doi:
694 10.1111/myc.13353. Epub ahead of print. PMID: 34255907.
- 695 53) Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, Uncontrolled diabetes and
696 corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial
697 region? A retrospective, multi-centric analysis. *J Maxillofac Oral Surg*. Epub ahead of
698 print 6 March 2021. DOI: 10.1007/s12663-021-01532-1.
- 699 54) Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, Rezaie Y, Rajaeih
700 S, Alijani N, Barac A, Abdollahi A, Khodavaisy S. Mucormycosis in patients with
701 COVID-19: A cross-sectional descriptive multicentre study from Iran. *Mycoses*. 2021

- 702 Jun 7:10.1111/myc.13334. doi: 10.1111/myc.13334. Epub ahead of print. PMID:
703 34096653; PMCID: PMC8242414.
- 704 55) Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical
705 profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral
706 mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on
707 Mucormycosis in COVID-19 (COSMIC), Report 1. *Indian J Ophthalmol.* 2021;69
708 (7):1670-1692. doi:10.4103/ijo.IJO_1565_21.
- 709 56) Ramaswami A, Sahu AK, Kumar A, Suresh S, Nair A, Gupta D et al. COVID-19
710 associated Mucormycosis Presenting to the Emergency Department - An Observational
711 Study of 70 Patients. *QJM.* 2021 Jul 12: hcab190. doi: 10.1093/qjmed/hcab190. Epub
712 ahead of print. PMID: 34254132.
- 713 57) Pal R, Singh B, Bhadada SK, Banerjee M, Bhogal RS, Hage N et al. COVID-19-
714 associated mucormycosis: An updated systematic review of literature. *Mycoses.* 2021
715 Jun 16. doi: 10.1111/myc.13338. Epub ahead of print. PMID: 34133798.
- 716 58) Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic
717 review of cases reported worldwide and in India. *Diabetes Metab Syndr.* 2021 May
718 21;15 (4):102146. doi: 10.1016/j.dsx.2021.05.019. Epub ahead of print. PMID:
719 34192610; PMCID: PMC8137376.
- 720 59) Mishra Y, Prashar M, Sharma D, Akash Kumar VP, Tilak TVSVGK. Diabetes, COVID
721 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center
722 in Western India. *Diabetes Metab Syndr.* 2021 Jul 3;15 (4):102196. doi:
723 10.1016/j.dsx.2021.102196. Epub ahead of print. PMID: 34246939; PMCID:
724 PMC8253699.
- 725 60) Kumari A, Rao NP, Patnaik U, Malik V, Tevatia MS, Thakur S et al. Management
726 outcomes of mucormycosis in COVID-19 patients: A preliminary report from a tertiary
727 care hospital. *Med J Armed Forces India.* 2021 Jul;77: S289-S295. doi:
728 10.1016/j.mjafi.2021.06.009. Epub 2021 Jul 26. PMID: 34334896; PMCID:
729 PMC8313063.
- 730 61) Dubey S, Mukherjee D, Sarkar P, Mukhopadhyay P, Barman D, Bandopadhyay M et al.
731 COVID-19 associated rhino-orbital-cerebral mucormycosis: An observational study

- 732 from Eastern India, with special emphasis on neurological spectrum. *Diabetes Metab*
733 *Syndr.* 2021 Sep 1:102267. doi: 10.1016/j.dsx.2021.102267. Epub ahead of print.
734 PMID: PMC8407938.
- 735 62) CLINICAL MANAGEMENT PROTOCOL: COVID-19. Government of India Ministry
736 of Health and Family Welfare Directorate General of Health Services (EMR Division).
737 Version 5. Published May 2021. Available at:
738 [https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated0](https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf)
739 [3072020.pdf](https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf).
- 740 63) Guideline for management of Mucormycosis in Covid – 19 patients. Government of
741 India Ministry of Health and Family Welfare Directorate General of Health Services
742 (EMR Division). Available at:
743 [https://dghs.gov.in/WriteReadData/News/202105171119301555988Mucormycosismana](https://dghs.gov.in/WriteReadData/News/202105171119301555988MucormycosismanagementinCovid-19.pdf)
744 [gementinCovid-19.pdf](https://dghs.gov.in/WriteReadData/News/202105171119301555988MucormycosismanagementinCovid-19.pdf)
- 745 64) Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis
746 and management of mucormycosis: an initiative of the European Confederation of
747 Medical Mycology in cooperation with the Mycoses Study Group Education and
748 Research Consortium. *Lancet Infect Dis* 2019; 19: e405–e421.
- 749 65) Shah K, Dave V, Bradoo R, Shinde C, Prathibha M. Orbital Exenteration in Rhino-
750 Orbito-Cerebral Mucormycosis: A Prospective Analytical Study with Scoring
751 System. *Indian J Otolaryngol Head Neck Surg.* 2019; 71 (2):259-265.
752 doi:10.1007/s12070-018-1293-8.
- 753 66) Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro Let al. Chest CT score in
754 COVID-19 patients: correlation with disease severity and short-term prognosis. *Eur*
755 *Radiol.* 2020 Dec; 30(12): 6808-6817. <https://doi.org/10.1007/s00330-020-07033-y>.
- 756 67) AIIMS/ICMR-COVID-19 National Task force/Joint monitoring group (Dte GHS).
757 Ministry of health and family welfare, Government of India. Clinical guidance for
758 management of adult COVID-19 patients. Published 17th May 2021. Available at:
759 <https://covid.aiims.edu/clinical-guidance-for-management-of-adult-covid-19-patients/>
- 760 68) Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RLet al.
761 Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect*

762 Dis. 2005 Sep 1; 41(5):634-53. doi: 10.1086/432579. Epub 2005 Jul 29. PMID:
763 16080086.

764 69) World health organization (WHO): COVID-19 Clinical management: living guidance.
765 Accessed 1st September 2021. Available at:
766 <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>

767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809

810 **Table 1: Epidemiology of COVID-19 admission in Mucormycosis patients**

Baseline characteristics	Total (N=59) n (%)	Discharged (n=44) n (%)	Death (n=15) n (%)	p-value
Age (Years)				0.077
≤ 60 years	42 (71.2)	34 (77.3)	8 (53.3)	
> 60 years	17 (28.8)	10 (22.7)	7 (46.7)	
Median (IQR)	52 (41, 61)	50 (40, 58)	57 (42, 65)	0.136
Gender				0.481
Male	47 (79.7)	36 (81.8)	11 (73.3)	
Female	12 (20.3)	8 (18.2)	4 (26.7)	
Co-morbidities				
Diabetes Mellitus				0.216
Non-diabetic	6 (10.2)	5 (11.4)	1 (6.7)	
Known Diabetes Mellitus	36 (61.0)	24 (54.5)	12 (80.0)	
Newly diagnosed DM/ IFG	17 (28.8)	15 (34.1)	2 (13.3)	
Hypertension	24 (40.7)	17 (38.6)	7 (46.7)	0.585
Chronic kidney disease	9 (15.3)	6 (13.6)	3 (20.0)	0.680
Ischemic Heart Disease	7 (11.9)	4 (9.1)	3 (20.0)	0.355
Chronic liver disease	2 (3.4)	0 (0.0)	2 (13.3)	0.061
Stroke	1 (1.7)	0 (0.0)	1 (6.7)	0.254
HIV/ Hepatitis B infection	1 (1.7)	1 (2.3)	0 (0.0)	>0.999
Obesity	2 (3.4)	1 (2.3)	1 (6.7)	0.447
Hypo/hyperthyroidism	3 (5.1)	2 (4.5)	1 (6.7)	>0.999
Severity of COVID-19				0.223
Mild	16 (27.1)	12 (27.3)	4 (26.7)	
Moderate	29 (49.2)	24 (54.5)	5 (33.3)	
Severe	14 (23.7)	8 (18.2)	6 (40.0)	
HRCT chest COVID severity score				0.047
< 18	55 (93.2)	43 (97.7)	12 (80.0)	
≥ 18	4 (6.8)	1 (2.3)	3 (20.0)	
Median (IQR)	12 (8, 15)	12 (8, 14)	14 (8, 17)	0.152
COVID-19 admission Median(IQR)				
Duration of hospitalization (days)	9 (6, 14)	8 (6, 13.5)	10 (7, 15)	0.149
Duration of ICU stay (days)	0 (0, 10)	0 (0, 0)	0 (0, 10)	0.303
Duration of ventilation (days)	0 (0, 10)	0 (0, 0)	0 (0, 10)	0.046
COVID-19 vaccine status				0.826
No vaccination	46 (78.0)	34 (77.3)	12 (80.0)	
AstraZeneca - 1 dose	9 (15.3)	7 (15.9)	2 (13.3)	
AstraZeneca - 2 doses	2 (3.4)	1 (2.3)	1 (6.7)	
Covaxin (Bharat Biotech) - 1 dose	1 (1.7)	1 (2.3)	0 (0.0)	
Covaxin (Bharat Biotech)- 2 dose	1 (1.7)	1 (2.3)	0 (0.0)	

811

812 DM- Diabetes mellitus; IFG- Impaired fasting glucose; HRCT- High resolution computerized
813 tomography; HIV- Human immunodeficiency virus

814

815

816 **Table 2a: Drugs administered during COVID-19 treatment**

Concomitant drugs	Total (N=59) n (%)	Discharged (n=44) n (%)	Death (n=15) n (%)	p-value
Meropenem	18 (30.5)	13 (29.5)	5 (33.3)	0.783
Teicoplanin	12 (20.3)	7 (15.9)	5 (33.3)	0.148
Clindamycin	0 (0.0)	0 (0.0)	0 (0.0)	
Doxycycline	25 (42.4)	19 (43.2)	6 (40.0)	0.829
Ivermectin	16 (27.1)	13 (29.5)	3 (20.0)	0.473
Piperacillin-Tazobactam	34 (57.6)	24 (54.5)	10 (66.7)	0.412
Polymyxin	2 (3.4)	0 (0.0)	2 (13.3)	0.061
Fluconazole	12 (20.3)	7 (15.9)	5 (33.3)	0.148
Caspofungin	2 (3.4)	0 (0.0)	2 (13.3)	0.061
Favipravir	35 (59.3)	25 (56.8)	10 (66.7)	0.503
Remdesivir	40 (67.8)	29 (65.9)	11 (73.3)	0.595
Hydroxychloroquine (HCQ)	0 (0.0)	0 (0.0)	0 (0.0)	
Azithromycin	4 (6.8)	4 (9.1)	0 (0.0)	0.564
Lopinavir/ritonavir	0 (0.0)	0 (0.0)	0 (0.0)	
Famotidine	0 (0.0)	0 (0.0)	0 (0.0)	
Enoxaparin	52 (88.1)	37 (84.1)	15 (100)	0.174
Immunomodulator therapy				
Not given	46 (78)	36 (81.8)	10 (66.7)	
Itolizumab	1 (1.7)	1 (2.3)	0 (0.0)	
Baricitinib	2 (3.4)	2 (4.5)	0 (0.0)	
Bevacizumab	2 (3.4)	2 (4.5)	0 (0.0)	
Bevacizumab+Infliximab	1 (1.7)	1 (2.3)	0 (0.0)	
Idofinib	1 (1.7)	1 (2.3)	0 (0.0)	
Infliximab	1 (1.7)	0 (0.0)	1 (6.7)	
Tocilizumab	5 (8.5)	1 (2.3)	4 (26.7)	
Convalescent Plasma	4 (6.8)	3 (6.8)	1 (6.7)	>0.999
Pirfenidone	12 (20.3)	6 (13.6)	6 (40.0)	0.028
Nintedanib	10 (16.9)	5 (11.4)	5 (33.3)	0.050
Dialysis	1 (1.7)	0 (0.0)	1 (6.7)	0.254
Noradrenaline	3 (5.1)	0 (0.0)	3 (20.0)	0.014
Vasopressin	1 (1.7)	0 (0.0)	1 (6.7)	0.254

817

818

819 **Table 2b: Steroids and Supplemental Oxygen used during COVID-19 treatment**

Steroids/Oxygen use in COVID-19 treatment	Total (N=59) n (%)	Discharged (n=44) n (%)	Death (n=15) n (%)	p-value
Steroids given for treating COVID-19				
Methylprednisolone	54 (91.5)	40 (90.9)	14 (93.3)	>0.999
Dexamethasone	4 (6.8)	4 (9.1)	0 (0.0)	0.564
Oral Prednisolone	10 (16.9)	8 (18.2)	2 (13.3)	>0.999
Oral Deflazacort	1 (1.7)	1 (2.3)	0 (0.0)	>0.999
Oxygen given during treatment of COVID-19				
Nasal oxygen by prongs	5 (8.5)	5 (11.4)	0 (0.0)	0.315
Nasal oxygen by face mask	1 (1.7)	0 (0.0)	1 (6.7)	0.254
Nasal oxygen by NRBM	28 (47.5)	21 (47.7)	7 (46.7)	0.943
NRBM (days) Median (IQR)	7 (4, 10)	5 (4, 10)	7 (7, 10)	0.369
HFNO	2 (3.4)	1 (2.3)	1 (6.7)	0.447
HFNO (days) Median (IQR)	14 (10, 17)	17 (17, 17)	10 (10, 10)	0.317
NIV	7 (11.9)	3 (6.8)	4 (26.7)	0.062
NIV (days) Median (IQR)	8 (3, 15)	3 (3, 15)	9 (5, 14)	0.721
Invasive mechanical ventilation (IMV)	3 (5.1)	0 (0.0)	3 (20.0)	0.014
IMV (days) Median (IQR)	2 (1, 4)	0 (0, 0)	2 (1, 4)	

820 NRBM- Non re-breathing mask; IQR- Inter-quartile range; HFNO-High flow nasal oxygen; NIV- Non-
821 invasive ventilation; IMV- Invasive mechanical ventilation

822

823

824

825

826

827

828

829

830

831

832

833

834

835 **Table 3: Baseline characteristics of patients of Mucormycosis**

Mucormycosis	Total n (%)	Discharged n (%)	Death n (%)	p-value
Total patients	59	44 (74.6)	15 (25.4)	0.0002
Type of Mucormycosis				<0.0001
Rhinal involvement only	24 (40.7)	24 (54.5)	0 (0.0)	
Rhinal + Orbital involvement	8 (13.6)	7 (15.9)	1 (6.7)	
Rhinal + Orbital + Cerebral	25 (42.4)	13 (29.5)	12 (80.0)	
Rhinal + Cerebral	1 (1.7)	0 (0.0)	1 (6.7)	
Renal	1 (1.7)	0 (0.0)	1 (6.7)	
Symptoms of Mucormycosis				
Facial pain	42 (71.2)	32 (72.7)	10 (66.7)	0.654
Facial swelling	33 (55.9)	22 (50.0)	11 (73.3)	0.142
Headache	43 (72.9)	32 (72.7)	11 (73.3)	>0.999
Eye swelling	33 (55.9)	20 (45.5)	13 (86.7)	0.007
Eye pain	29 (49.2)	17 (38.6)	12 (80.0)	0.007
Loss of vision	21 (35.6)	9 (20.5)	12 (80.0)	<0.0001
Ptosis	21 (35.6)	11 (25.0)	10 (66.7)	0.004
Deviation of angle of mouth	5 (8.5)	3 (6.8)	2 (13.3)	0.593
Nasal discharge	15 (25.4)	13 (29.5)	2 (13.3)	0.310
Limb weakness	5 (8.5)	1 (2.3)	4 (26.7)	0.013
Toothache	27 (45.8)	24 (54.5)	3 (20.0)	0.034
Duration of symptoms (days)				
Median (IQR)	6 (3, 9)	6 (3, 10)	5 (3, 8)	0.488
Duration between 1st positive COVID-19 test and Mucormycosis diagnosis				0.751
< 7 days	2 (3.4)	2 (4.5)	0 (0.0)	
7-14 days	20 (33.9)	14 (31.8)	6 (40.0)	
15-28 days	28 (47.5)	20 (45.5)	8 (53.3)	
> 28 days	9 (15.3)	8 (18.2)	1 (6.7)	
Median (IQR)	17 (12, 22)	17 (13, 23)	17 (10, 21)	0.676

836 IQR- Interquartile range

837

838

839

840

841

842

843

844

845

846

847 **Table 4: Baseline investigations during admission for Mucormycosis**

Baseline characteristics	Total (N=59) n (%)	Discharged (n=44) n (%)	Death (n=15) n (%)	p-value
Laboratory investigations				
Hemoglobin (g/dL)	13.4 (11.4, 14.5)	13.75 (12.05, 14.5)	12.5 (10.9, 13.9)	0.169
WBC (per microliter)	10400 (7000, 14400)	10150 (7000, 13500)	11900 (7000, 15400)	0.568
Absolute Neutrophil count (ANC)	8100 (5248, 11475)	7902 (5214, 11260)	9559 (5250, 13490)	0.447
Platelet count	227000 (178000, 308000)	231000 (189000, 308500)	198000 (160000, 308000)	0.186
Total Bilirubin (mg/dL)	1.035 (0.83, 1.36)	1.06 (0.85, 1.335)	0.905 (0.7, 1.41)	0.369
Direct Bilirubin conjugated (mg/dL)	0.315 (0.26, 0.46)	0.325 (0.26, 0.46)	0.295 (0.24, 0.6)	0.601
SGOT (units/L)	31 (18, 50)	28 (18, 40)	45 (32, 53)	0.054
SGPT (units/L)	35 (23, 52)	35 (22, 45)	47.5 (33, 99)	0.071
Blood urea level (mg/dL)	32 (22, 54)	28 (20.5, 49)	41 (27, 92)	0.030
Serum Creatinine (mg/dL)	1.1 (0.96, 1.27)	1.085 (0.96, 1.205)	1.12 (1.02, 1.61)	0.261
Potassium (mmol/L)	4 (3.5, 4.5)	4 (3.5, 4.4)	3.9 (3.2, 4.5)	0.656
Absolute Lymphocyte count (ALC, cells/mm³)				
< 1000	14 (24.6)	8 (18.2)	6 (46.2)	
≥ 1000	43 (75.4)	36 (81.8)	7 (53.8)	
Median (IQR)	1350 (1010, 1750)	1407.5 (1185, 1996.5)	1045 (595, 1308)	0.008
Procalcitonin (ng/mL)				
< 0.05	1 (2.5)	0 (0)	1 (9.1)	
0.05-2.0	28 (70)	22 (75.9)	6 (54.5)	
> 2.0	11 (27.5)	7 (24.1)	4 (36.4)	
Median (IQR)	0.38 (0.2085, 2.735)	0.392 (0.207, 1.56)	0.341 (0.212, 3.81)	0.797
C-reactive Protein (mg/L)				
0-6	2 (4.7)	2 (6.3)	0 (0)	
7-49	9 (20.9)	8 (25)	1 (9.1)	
≥ 50	32 (74.4)	22 (68.8)	10 (90.9)	
Median (IQR)	84.7 (41, 167)	74.25 (39, 138.75)	173.735 (64.3, 207.5)	0.032
Ferritin (mcg/L)				
15-150	3 (9.4)	3 (12.5)	0 (0)	
151-1000	16 (50)	13 (54.2)	3 (37.5)	
> 1000	13 (40.6)	8 (33.3)	5 (62.5)	
Median (IQR)	857.1 (280.5, 1429)	677.25 (262.55, 1108)	1346.5 (720.55, 1817.5)	0.089
D-Dimer (mcg/mL)				
< 252	9 (24.3)	7 (25.9)	2 (20)	
253-1000	17 (45.9)	13 (48.1)	4 (40)	
> 1000	11 (29.7)	7 (25.9)	4 (40)	
Median (IQR)	483.5 (253.73, 1201.00)	427.1 (237.08, 1071.71)	566.9 (255.48, 20)	0.321

848 WBC- White blood cell; IQR- Interquartile range; SGPT- Serum glutamate pyruvate transaminase;
849 SGOT- Serum glutamate oxaloacetate transaminase.

850 **Table 5: Treatment regimens used in Mucormycosis**

Treatment regimen for Mucormycosis	Total (N=59) n (%)	Discharged (n=44) n (%)	Death (n=15) n (%)	p-value
Drugs administered				
Liposomal Amphotericin B	53 (89.8)	42 (95.5)	11 (73.3)	0.032
Amphotericin B lipid complex/emulsion	17 (28.8)	17 (38.6)	0 (0.0)	0.003
Amphotericin B de-oxycholate	27 (45.8)	22 (50)	5 (33.3)	0.263
Total Amphotericin days				0.015
Not given	5 (8.5)	1 (2.3)	4 (26.7)	
≤ 21 days	30 (50.8)	20 (45.5)	10 (66.7)	
> 21 days	24 (40.7)	23 (52.3)	1 (6.7)	
Median (IQR)	21 (14, 27)	22 (15, 28)	10 (6, 21)	0.004
Posaconazole	58 (98.3)	44 (100)	14 (93.3)	0.254
Isavuconazole	5 (8.5)	5 (11.4)	0 (0.0)	0.315
Antibiotics given	55 (93.2)	40 (90.9)	15 (100.0)	0.564
Name of antibiotics				
Amoxicillin-Clavulanate	8 (13.6)	8 (18.2)	0 (0.0)	
Cefpodoxime	1 (1.7)	1 (2.3)	0 (0.0)	
Colistin	1 (1.7)	0 (0.0)	1 (6.7)	
Ceftriaxone-disodium edetate-sulbactam	2 (3.4)	2 (4.5)	0 (0.0)	
Cefoperazone-Sulbactam	1 (1.7)	1 (2.3)	0 (0.0)	
Meropenem	28 (47.5)	15 (34.0)	13 (86.7)	
Ceftriaxone	3 (5.1)	3 (6.8)	0 (0.0)	
Cefuroxime	1 (1.7)	1 (2.3)	0 (0.0)	
Piperacillin-Tazobactam	10 (16.9)	9 (20.5)	1 (6.7)	
Surgical procedures				
FESS	56 (94.9)	42(95.4)	14(93.3)	0.781
Orbital decompression	10 (16.9)	10 (22.7)	0 (0.0)	0.052
Palatal clearance	1 (1.7)	1 (2.3)	0 (0.0)	>0.999
Exenteration	13 (22)	6 (13.6)	7 (46.7)	0.008
Maxillectomy	9 (15.3)	9 (20.5)	0 (0.0)	0.095
Neurosurgery	5 (8.5)	3 (6.8)	2 (13.3)	0.593
Oxygenation and Ventilation data				
Nasal oxygen by prongs	1 (1.7)	0 (0.0)	1 (6.7)	0.254
Nasal oxygen by face mask	0 (0.0)	0 (0.0)	0 (0.0)	
Nasal oxygen by NRBM	5 (8.5)	4 (9.1)	1 (6.7)	>0.999
NRBM (days) Median (IQR)	13 (12, 14)	13 (12, 14)	ND	
HFNO	0 (0.0)	0 (0.0)	0 (0.0)	
NIV	2 (3.4)	0 (0.0)	2 (13.3)	0.061
NIV (days) Median (IQR)	2 (1, 2)	0 (0, 0)	2 (1, 2)	0.015
Invasive mechanical ventilation (IMV)	8 (13.6)	1 (2.3)	7 (46.7)	<0.0001
IMV (days) Median (IQR)	3 (2, 4)	3 (3, 3)	3 (2, 4)	<0.0001

ICU admissions

Required ICU	18 (30.5)	8 (18.2)	10 (66.7)	<0.0001
ICU stay (days) Median (IQR)	3 (3, 6)	3 (2, 7)	4 (3, 5)	<0.0001

851 FESS – Functional endoscopic sinus surgery; NRBM – Non re-breathing mask; IQR- Interquartile range;

852 HFNO- High flow nasal oxygen; NIV- Non-invasive ventilation; IMV – Invasive mechanical ventilation.

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879 **Table 6: Complications in Mucormycosis patients during antifungal therapy**

Complications in Mucormycosis	Total (N=59) n (%)	Discharged (n=44) n (%)	Death (n=15) n (%)	p-value
Complications				
Acute kidney injury	30 (50.8)	22 (50)	8 (53.3)	0.824
Hypokalemia	52 (88.1)	40 (90.9)	12 (80.0)	0.355
Hepatitis	20 (33.9)	12 (27.3)	8 (53.3)	0.066
Fever	46 (78.0)	35 (79.5)	11 (73.3)	0.721
Chills	45 (76.3)	34 (77.3)	11 (73.3)	0.757
Loose motions	14 (23.7)	11 (25.0)	3 (20.0)	>0.999
Vomiting	21 (35.6)	15 (34.1)	6 (40.0)	0.680
Loss of appetite	46 (78.0)	35 (79.5)	11 (73.3)	0.721
Abdominal pain	9 (15.3)	5 (11.4)	4 (26.7)	0.213
Abdominal Distension	2 (3.4)	1 (2.3)	1 (6.7)	0.447
Thrombophlebitis	35 (59.3)	29 (65.9)	6 (40.0)	0.078
Stomatitis	20 (33.9)	15 (34.1)	5 (33.3)	0.957
Pedal edema	14 (23.7)	9 (20.5)	5 (33.3)	0.311
Anemia	34 (57.6)	22 (50.0)	12 (80.0)	0.068
Thrombocytopenia	14 (23.7)	6 (13.6)	8 (53.3)	0.002
Osteomyelitis	11 (18.6)	10 (22.7)	1 (6.7)	0.259
Stroke/ Cerebritis	15 (25.4)	2 (4.5)	13 (86.7)	<0.0001

880

881

882

883

884

885

886

887

888

889

890

891

892


893

894 **Table 7: Relative risk of death in Mucormycosis patients**

Factors	Relative risk (95% CI)	p-value
Age > 60 years (Ref: ≤ 60 years)	2.162 ((0.9300, 5.0251)	0.098
Male (Ref: Female)	0.702 (0.2708, 1.8205)	0.506
Diabetes Mellitus (Ref: Diabetic)		
Newly diagnosed/ pre-diabetic	0.353 (0.0887, 1.4048)	0.052
COVID-19 related factors		
HRCT score ≥ 18 (Ref: < 18)	3.438 (1.6153, 7.3155)	0.017
Irrational use of steroids (Ref: Rational use)	0.689 (0.2875, 1.6530)	0.407
Not vaccinated against COVID-19 (Ref: vaccinated)	1.130 (0.3743, 3.4139)	0.822
Duration between 1st COVID-19 test and Mucormycosis diagnosis ≥ 15 days (Ref: <15 days)	0.892 (0.3670, 2.1676)	0.803
Duration between COVID-19 discharge and Mucormycosis admission ≥ 15 days (Ref: <15 days)	0.671 (0.1764, 2.5556)	0.544
Type of Mucormycosis (Ref: Rhino only)		
Rhinal + Orbital	0.455 (0.0690, 3.0048)	0.259
Rhinal + Orbital + Cerebral	5.440 (1.7140, 17.2662)	0.0004
Symptoms of Mucormycosis (Ref: No symptom)		
Facial pain	0.810 (0.3246, 2.0187)	0.663
Facial swelling	2.167 (0.7794, 6.0234)	0.098
Headache	1.023 (0.3802, 2.7539)	0.964
Eye swelling	5.121 (1.2665, 20.7087)	0.002
Eye pain	4.138 (1.3003, 13.1684)	0.003
Loss of vision	7.238 (2.2978, 22.8006)	<0.0001
Ptosis	3.619 (1.4252, 9.1899)	0.005
Deviation of angle of mouth	1.662 (0.5140, 5.3715)	0.482
Nasal discharge	0.451 (0.1148, 1.7733)	0.146
Limb weakness	3.927 (1.9784, 7.7961)	0.001
Toothache	0.296 (0.0932, 0.9422)	0.012
Investigations in Mucormycosis		
Diabetic Ketoacidosis (Ref: No)	3.267 (1.5012, 7.1085)	0.011
Blood urea level	1.023 (1.0013, 1.0452)	0.0002
ALC ≥ 1000 (Ref: < 1000)	0.379 (0.1531, 0.9422)	0.065
Procalcitonin > 2 (Ref: ≤ 2)	1.507 (0.5467, 4.1513)	0.460
C-reactive Protein ≥ 50 (Ref: < 50)	3.438 (0.4949, 23.8759)	0.063
Ferritin > 1000 (Ref: ≤ 1000)	2.436 (0.7011, 8.4634)	0.153
D-Dimer > 252 (Ref: ≤ 252)	1.286 (0.3315, 4.9860)	0.697
Treatment days in Mucormycosis (Ref: ≤ 21 days)		
Total Amphotericin days > 21 days	0.125 (0.0172, 0.9093)	0.002
Posaconazole > 21 days	0.364 (0.1293, 1.0228)	0.055
Complications in Mucormycosis (Ref: No complication)		
Hepatitis	2.229 (0.9437, 5.2628)	0.079
Thrombophlebitis	0.457 (0.1872, 1.1164)	0.083
Anemia	2.941 (0.9267, 9.3351)	0.067

	Thrombocytopenia	3.674 (1.6211, 8.3244)	0.004
	Stroke/ Cerebritis	19.067 (4.8522, 74.9224)	<0.0001
895	ALC- Absolute lymphocyte count		

896



897

898 Figure 1: Prevalence of risk factors in Mucormycosis patients who died

899




Figure 1: Prevalence of risk factors in Mucormycosis patients who died